Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • News
  • FDA approves Sanofi’s Infilbray for Gaucher disease type 3
  • News

FDA approves Sanofi’s Infilbray for Gaucher disease type 3

The FDA approved Sanofi's Infilbray for Gaucher disease type 3 and Regeneron's Livsayis for generalized myasthenia gravis, while Insmed shares rose 20% on reports of a Sanofi takeover approach.
pharminent November 20, 2026

Pharminent · Daily Brief
November 20, 2026

Regulatory & Approvals

FDA approves Sanofi’s Infilbray for Gaucher disease type 3
Sanofi’s Infilbray (venglustat), a brain-penetrating small molecule, has been approved by the FDA for the treatment of Gaucher disease type 3. It is the first FDA-approved therapy for the neurological symptoms of the rare enzyme deficiency.
MedCity News →$SNY

FDA approves Regeneron’s RNAi drug Livsayis in myasthenia gravis
The FDA approved Regeneron’s Livsayis (cemdisiran), an siRNA therapy for generalized myasthenia gravis developed through a collaboration with Alnylam. It is Regeneron’s first marketed RNAi drug.
BioPharma Dive →$REGN$ALNY

Clinical Data

Recursion secures FDA alignment on phase 3 endpoint for FAP therapy
Recursion’s CEO detailed a novel phase 3 endpoint for the company’s familial adenomatous polyposis therapy, saying the biotech has secured FDA alignment on the pivotal trial design. The study is planned to start in 2027.
Pharmaceutical Technology →

Deals & Partnerships

Insmed shares jump 20% on reported Sanofi takeover interest
Insmed’s shares rose 20% on rumors that Sanofi is considering a takeover of the company, while Sanofi’s stock fell 2%. Analysts backed the rationale for a potential deal.
Pharmaceutical Technology →$SNY$INSM

Prostate Progress expands through alliance with Macmillan Cancer Support
Prostate Progress, a data-powered project seeking better tests, treatments and care for prostate cancer, is expanding through an alliance with Macmillan.
Pharmaphorum →

Business & Finance

Large drugmakers tell House panel they will halt some China trials
Large drugmakers told a U.S. House committee that they will halt clinical trials at some hospitals in China.
STAT →

USPTO institutes Amneal, Kashiv IPR on Genentech omalizumab patent
On November 10, 2026, the U.S. Patent and Trademark Office granted institution of inter partes review in IPR2026-00260, filed by Amneal Pharmaceuticals and Kashiv BioSciences against U.S. Patent No. 12,030,959, owned by Genentech and Novartis.
Big Molecule Watch →$RHHBY$NVS

Forwarded this? Get your copy free
Sign up free →

Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.

Post navigation

Previous: Pfizer signs $2.6B in vivo CAR-T deal with Starna

Related Stories

  • News

Pfizer signs $2.6B in vivo CAR-T deal with Starna

pharminent November 19, 2026
  • News

FDA approves Beren’s Lembaz for Niemann-Pick disease type C

pharminent November 18, 2026
  • News

FDA approves Roche’s oral SERD Wilserdly for breast cancer

pharminent November 17, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.